Jazz Pharmaceuticals (NASDAQ:JAZZ) announced disappointing results from its Phase 2 clinical trial of JZP150, a drug developed for treating post-traumatic stress disorder (PTSD). The trial aimed to assess the effectiveness and safety of JZP150 but failed to achieve its primary goal of significantly reducing PTSD symptoms.

Rob Iannone, the Executive Vice President and Global Head of Research and Development at Jazz Pharmaceuticals, commented on the trial's outcome. He indicated that while the company acknowledges the ongoing need for effective PTSD treatments, it does not foresee further development of JZP150 for this condition.